GlassScriptPhysician profile
Omeni N Osian
NPI 1487727079
$10,868.23
in general payments reported to CMS, 2019-2025
12 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,439 · 2020: $349 · 2021: $126 · 2022: $1,317 · 2023: $411 · 2024: $1,244 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269 · Travel and Lodging: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.32 |
| Travel and Lodging | $368.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,508.70 | 2019-2020 | |
| Abiomed | $1,657.01 | 2022-2025 | Impella |
| Abbott Laboratories | $1,101.21 | 2022 | |
| Edwards Lifesciences Corporation | $786.02 | 2019-2025 | Sapien 3 Ultra Resilia |
| Atricure, INC. | $595.00 | 2019-2024 | |
| Medtronic, INC. | $592.81 | 2021-2024 | Corevalve Evolut R, Avalus, Micra |
| Medtronic Vascular, INC. | $329.52 | 2019-2020 | |
| Cvrx, INC. | $127.07 | 2025 | Barostim Neo System |
| Penumbra, INC. | $119.56 | 2024 | Penumbra System |
| Getinge USA Sales, LLC | $19.15 | 2020 | |
| Ethicon INC. | $16.40 | 2021 | |
| Lsi Solutions INC | $15.78 | 2023 | Cor Knot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omeni Osian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.